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Abstract
Background: Serum lipid profiles may be influenced by thyroid function, but the detailed mechanism remains
unclear. Increasing evidence suggests that thyrotropin (TSH) may exert extra-thyroidal effects. The goal of this study
was to evaluate the relationship between serum TSH levels and the lipid profiles in euthyroid non-smokers with
newly diagnosed asymptomatic coronary heart disease (CHD).
Methods: This was a retrospective study of 406 euthyroid non-smokers (187 males and 219 females) with newly
diagnosed asymptomatic CHD from 2004 to 2010 in Jinan, China. Lipid parameters and the levels of TSH, FT3, and
FT4 were determined. Multiple linear regression analysis and Logistic regression analysis were used to assess the
influence of TSH on the lipid profiles and the risks of dyslipidemia.
Results: The TSH level, even within the normal range, was positively and linearly correlated with total cholesterol (TC),
non-high density lipoprotein cholesterol (non-HDL-C) and triglycerides (TG) (Beta = 0.173, 0.181 and 0.103, respectively,
P < 0.01 in all). With 1 mIU/L rise of TSH, the levels of TC, TG and non-HDL-C will increase by 1.010, 1.064, and 1.062
mmol/L, respectively. The odds ratio of hypercholesterolemia and hypertriglyceridemia with respect to the serum TSH
level was 1.640 (95% CI 1.199-2.243, P = 0.002) and 1.349 (95% CI 1.054-1.726, P = 0.017), respectively.
Conclusions: TSH levels were correlated in a positive linear manner with the TC, non-HDL-C and TG levels in
euthyroid non-smokers with newly diagnosed asymptomatic CHD. TSH in the upper limits of the reference range
might exert adverse effects on lipid profiles and thus representing as a risk factor for hypercholesterolemia and
hypertriglyceridemia in the context of CHD.
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Background
In recent years, more and more evidence has demon-
s t r a t e dt h a th y p o t h y r o i d i s mi sa s s o c i a t e dw i t ht h e
increased prevalence of CHD [1,2]. This association is
partly due to decreased levels of thyroid hormones,
which lead to an atherogenic lipid profile characterized
by increased levels of total cholesterol (TC) and low-
density lipoprotein cholesterol (LDL-C) [3]. In the past
decades, some studies indicate that subclinical hypothyr-
oidism (SCH), which is defined as normal levels of
serum free triiodothyronine (FT3) and free thyroxine
(FT4) as well as elevated levels of thyrotropin (TSH), is
also associated with a moderate increase in the risk of
CHD [4,5]. Moreover, some researchers indicate that
variations of serum TSH levels within the normal refer-
ence range are related to the TC, TG, and LDL-C [6,7],
although not all investigations confirm these associa-
tions [8,9]. These findings imply that the association
* Correspondence: Houyinglong@sina.com; gaoling1@medmail.com.cn
5Department of Cardiology, Shandong Provincial Qianfoshan Hospital,
Shandong University, Jinan, People’s Republic of China
6Department of Central Laboratory, Provincial Hospital affiliated to Shandong
University, Jinan, People’s Republic of China
Full list of author information is available at the end of the article
Wanjia et al. Lipids in Health and Disease 2012, 11:44
http://www.lipidworld.com/content/11/1/44
© 2012 Wanjia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.between lipid levels and thyroid function cannot be fully
explained by the effects of FT3 and FT4 alone. We
assumed that TSH, the most sensitive parameter reflect-
ing the abnormal thyroid function in the early stage,
might participate in the regulation of lipid profile to
some extent.
TSH responds significantly and precisely to minor
changes in the concentrations of circulating thyroid hor-
mones. A considerable amount of researches on the
possible extrathyroidal effects of TSH has been pub-
lished. For example, positive associations between the
TSH level and waist circumference, body mass index
and blood pressure have been described [10-12]. Regard-
ing lipid metabolism, our previous study [13] indicated
that TSH might up-regulate hepatic 3-hydroxy-3-
methyl-glutaryl coenzyme A reductase (HMGCR)
expression, which suggested a potential direct role of
TSH in the cholesterol biosynthesis in the liver.
In addition, most studies concerning the relationship
between thyroid function and either CHD or the lipid
profile had included both smokers and non-smokers.
However, it is well known that smoking is also a risk
factor for CHD [14]. Furthermore, some population-
based study has indicated that smokers have lower levels
o fT S H[ 1 5 ] .T h u s ,i nt h i ss t u d y ,w em a i n l yf o c u s e do n
the possible association between TSH and the lipid pro-
files in euthyroid non-smokers with newly diagnosed
asymptomatic CHD.
Results
The relationship of TSH and lipid profiles in the study
population
Data concerning basic clinical characteristics, including
history of diabetes mellitus, history of hypertension,
drinking history, TSH, lipid profiles, FBG, UA, positivity
of antithyroid antibody, SBP and DBP in the study
population were shown in Table 1.
According to the results of a simple correlation, FT3
and FT4 were not correlated with the log-transformed
value of lipid profiles in these subjects. As expected,
FT4 was closely and negatively correlated with TSH(r =
-0.204, P < 0.01) and FT3 was positively correlated with
FT4(r = 0.204, P < 0.01). Moreover, there were positive
linear associations between the serum TSH levels and
the log-transformed values of both TC (Figure 1-a) and
non-HDL-C levels (Figure 1-b) (P < 0.01). TSH level
was also positively and linearly associated with log-
transformed TG, albeit weak but significant (R
2 = 0.011,
P < 0.05, data not shown). Because FT4 and FT3 are
negatively correlated with the TSH level, we did not
enter them into the same model in multiple linear
regression analysis. Within the normal range, TSH was
significantly associated with the log-transformed TC
levels (Beta = 0.173, P = 0.001), TG levels (Beta = 0.103,
P = 0.049) and non-HDL-C levels (Beta = 0.181, P <
0.001) (Table 2). No evidence was found for an associa-
tion between the TSH levels and the log-transformed
values of HDL-C and LDL-C. In model 2 including FT3
and FT4 in the regression analysis, only FT3 was posi-
tively correlated with the log-transformed values of
HDL-C (Beta = 0.101, P = 0.046). After an anti-log
transformation, the results showed that for every 1
mIU/L increase in the TSH levels across the entire
reference range, the levels of TC, TG and non-HDL-C
will increase by 1.010, 1.064, and 1.062 mmol/L,
respectively.
Comparison of lipid profiles among different TSH
categories within the normal range
Clinical characteristics of the subjects in different TSH
categories were shown in Table 3. Only FBG in G3 and
G4 were significantly lower than that in G1 (P <0 . 0 5
and P <0 . 0 1 ,r e s p e c t i v e l y ) .N osignificant differences
existed concerning the levels of FT3, FT4, UA, SBP,
DBP and antibody positivity among the four TSH
categories.
Table 4 showed the association between TSH within
the normal range and concentrations of serum lipids.
The lipid concentrations were log-transformed due to
non-normal distribution. Analysis of variance (ANOVA)
was performed by LSD (least significant difference) in
comparison of lipids in G2, G3 and G4 with that in G1
as the control. There was a consistent and significant
increase in concentrations of TC, TG and non-HDL-C,
Table 1 Clinical characteristics of the study population
characteristic N = 406
Male 187(46.10)
Age (yr) 64.38 ± 10.69
History of hypertension 290(71.43)
History of DM 62(15.27)
Drinking history 51(12.56)
TSH (mIU/L) 1.81(1.46)
TC (mmol/L) 5.05(1.37)
Non-HDL-C (mmol/L) 3.73(1.38)
TG (mmol/L) 1.40(0.96)
LDL-C (mmol/L) 3.00(1.04)
HDL-C (mmol/L) 1.26(0.49)
FBG (mmol/L) 5.82 ± 1.74
UA (mmol/L) 322.46 ± 109.11
SBP (mmHg) 135(30)
DBP (mmHg) 80(17)
Antithyroid antibody Positivity 93(22.91)
Data are presented as means ± standard deviations, medians (interquartile
ranges) or number (percentage).
DM, diabetes mellitus; TSH, thyrotropin; TC, total cholesterol; non-HDL-C, non-
high-density lipoprotein cholesterol; TG, triglyceride; LDL-C, low-density
lipoprotein cholesterol; FBG, fasting blood glucose; UA, uric acid; DBP, diastolic
blood pressure; SBP, systolic blood pressure
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more importantly, among the three catrgories (G2, G3
and G4), the log-transformed values of the above lipid
parameters increased the most significantly in G4 (TSH
2.5-4.8 mIU/L) than the other two categories when
compared with that in G1(P < 0.01 in all). While, the
log-transformed LDL-C level was only significantly
higher in G2 than that in G1 (P <0 . 0 5 ) .T h i st r e n d
maintained substantially when G3 and G4 were com-
pared with G1, although not reaching statistical signifi-
cance (P = 0.40 and 0.09, respectively).
The relationship of TSH and the prevalence of
hypercholesterolemia and hypertriglyceridemia
The prevalences of hypercholesterolemia, hypertriglycer-
idemia, high LDL-C and low HDL-C were 14.3%, 33.5%,
9.1%, and 5.7% respectively among the study population.
As shown in Figure 2-a, the prevalence of hypercholes-
terolemia in G2 and G3 was four times higher than that
in G1 (P < 0.01 and P < 0.05, respectively). For hypertri-
glyceridemia, the prevalence was approximately 2-folds
greater in G2, G3 and G4 than that in G1 (P < 0.05, P <
0.01 and P < 0.01, respectively). In G4, the prevalence of
hypercholesterolemia was five times higher than that in
G1(0.3-0.99 mIU/L). The prevalence of abnormal LDL
levels was also higher in G2 and G3 than that in G1 (P
<0 . 0 5a n dP < 0.01, respectively). There were no differ-
ences in the prevalence of low HDL-C among the four
TSH categories.
After adjusting for the confounding factors, logistic
regression analysis showed that the TSH level was a sig-
nificant independent factors for predicting the risk of
both hypercholesterolemia and hypertriglyceridemia in
the study population. The serum TSH level was not
associated with the risk of either high LDL-C or low
HDL-C levels in these patients (Table 5).
Comparison of TSH level between different lipid groups
We further compared the levels of serum TSH between
the abnormal and normal lipid groups by Mann-Whit-
ney test. The median of TSH was significantly higher in
hypercholesterolemic subjects than that in those with
normal TC levels (2.12 vs. 1.76 mmol/L, P = 0.002).
And compared with those had normal TG levels, the
median of TSH was also significantly higher in hypertri-
glyceridemic subjects (2.03 vs. 1.73 mmol/L, P =0 . 0 1 4 ) .
There were no differences in the median of TSH levels
between the abnormal and normal groups based on the
HDL-C and LDL-C levels (Figure 2-b).
Figure 1 Positive and linear association between TSH level and
log-transformed value of TC (a) or log-transformed value of
non-HDL-C (b) in euthyroid non-smokers with newly diagnosed
asymptomatic CHD (P < 0.01).
Table 2 Multiple linear regression of TSH with lipid profiles in euthyroid non-smokers with newly diagnosed
asymptomatic CHD
Log TC Log TG Log non-HDL-C Log LDL-C Log HDL-C
TSH* B (95%CI) Beta (P) B (95%CI) Beta (P) B (95%CI) Beta (P) Beta P Beta P
0.017(0.007-0.207) 0.173(0.001) 0.027(0.001-0.053) 0.103(0.049) 0.026(0.012-0.041) 0.181(< 0.001) 0.056 0.282 0.018 0.722
Data are B (unstandardized coefficients), 95% confidence interval (CI) of B, Beta (standardized coefficients) and P value for linear regression analysis of TSH, on
Log transform of total cholesterol (TC), triglyceride (TG), non-high-density lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL-C) and
high-density lipoprotein cholesterol (HDL-C).
* adjusted for sex, age, history of diabetes mellitus, history of hypertension, drinking history, fasting blood glucose and uric acid.
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It is generally accepted that overt hypothyroidism accel-
erates the progression of CHD by increasing levels of
TC and LDL-C. Whereas controversy still exists as to
whether there is an association between SCH and an
adverse lipid profile. Moreover, the issue of the associa-
tion between SCH and CHD remains complex [16,17].
Because there is a consensus that most of the CHD
patients should take statins, which might change the
lipid profiles, we chose to investigate those with newly
diagnosed asymptomatic CHD to avoid the confounding
effects of statins on lipid levels. Furthermore, to exclude
the possible confounding effects of smoking and to bet-
ter understand the role of TSH in CHD, we mainly
focused on euthyroid non-smokers in this study. We
found that even within the normal range, TSH was
positively and linearly correlated with lipid profiles in
non-smokers with newly diagnosed asymptomatic CHD.
Thyroid hormones play essential roles in a variety of
metabolic and developmental processes, and abnormal
thyroid hormone metabolism is one of the important
causes of coronary artery sclerosis [18]. Besides the
direct effects of FT3 and FT4, the relationship between
serum TSH concentration and metabolic effects has
been the focus of recent studies, which have yielded
conflicting results. One study in Japan found that com-
pared with the normal control subjects, CHD patients
had a relatively high level of TSH [19]. In a prospective
population-based study with a mean follow-up of 10.6
years [20], researchers demonstrated that within the
normal range, the TSH level was associated with TC,
LDL-C, and HDL-C more strongly than FT4 among
Table 3 Clinical characteristics of different TSH categories in 406 euthyroid non-smokers with newly diagnosed
asymptomatic CHD
G1
TSH
0.3-0.99 mIU/L
G2
TSH
1.0-1.89 mIU/L
G3
TSH
1.9-2.49 mIU/L
G4
TSH
2.5-4.8 mIU/L
N = 406 79(19.46%) 135(33.25%) 78(19.21%) 114(28.08)
Age (yr) 67.04 ± 10.63 64.59 ± 10.15 63.56 ± 11.32 63.20 ± 10.72
Male 40(50.6%) 69(51.1%) 41(52.6%) 37(32.5%)
DM history 15(19.0%) 24(17.8%) 12(15.4%) 12(12.3%)
Drinking history 4(5.1%) 21(15.6%) 12(15.4%) 14(12.3%)
Hypertension History 55(69.6%) 90(66.7%) 60(76.9%) 85(74.6%)
FT3 (pmol/L) 4.34 ± 0.75 4.44 ± 0.74 4.26 ± 0.64 4.26 ± 0.69
FT4 (pmol/L) 17.73 ± 2.56 17.26 ± 2.25 17.05 ± 2.44 16.38 ± 2.21
FBG (mmol/L) 6.26 ± 2.32 6.00 ± 1.82 5.53 ± 1.38* 5.49 ± 1.22**
UA (mmol/L) 330.72 ± 112.40 327.80 ± 100.85 314.83 ± 111.46 315.48 ± 115.29
DBP (mmHg) 80.00(24) 79.00(17) 80.00(12) 80(16)
SBP (mmHg) 135.00(25.00) 132.00(20.00) 132.00(27.75) 135.00(25)
Antithyroid antibody
positivity
16(25.8%) 33(30.6%) 13(19.7%) 31(31.6%)
Data are presented as means ± standard deviations, medians (interquartile ranges) or number (percentage).
DM, diabetes mellitus; FT3, free-triiodothyronine; FT4, free-thyroxine; FBG, fasting blood glucose; UA, uric acid; DBP, diastolic blood pressure; SBP, systolic blood
pressure
*P < 0.05 vs.G1; **P < 0.01 vs.G1
Table 4 Comparison of log-transformed lipid concentrations between different TSH categories in 406 euthyroid non-
smokers with newly diagnosed asymptomatic CHD
G1
TSH 0.3-0.99 mIU/L
G2
TSH
1.0-1.89 mIU/L
G3
TSH
1.9-2.49 mIU/L
G4
TSH
2.5-4.8 mIU/L
LogTC (mmol/L) 0.66 ± 0.10 0.70 ± 0.09** 0.70 ± 0.08* 0.71 ± 0.09**
LogTG (mmol/L) 0.09 ± 0.26 0.17 ± 0.22* 0.18 ± 0.24* 0.19 ± 0.24**
LogHDL-C(mmol/L) 0.10 ± 0.14 0.09 ± 0.12 0.10 ± 0.13 0.11 ± 0.11
LogLDL-C (mmol/L) 0.44 ± 0.11 0.48 ± 0.11* 0.46 ± 0.14 0.47 ± 0.14
LogNon-HDL-C (mmol/L) 0.51 ± 0.17 0.57 ± 0.10** 0.56 ± 0.13* 0.58 ± 0.13**
Data are presented as means ± standard deviations.
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density
lipoprotein cholesterol
* P < 0.0 5 and * *P < 0.01 vs. G1, respectively
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found a significant positive linear correlation between
serum TSH levels within the normal range and the
levels of TC and non-HDL-C. Similarly, a recent large
cohort study of Indian women with normal thyroid
function [21] also suggested that TSH in the upper lim-
its of the reference range (above 2.5 mIU/L) was asso-
ciated with higher TC.
In addition, our study showed that TSH was positively
correlated with TG, which was also observed in healthy
men in Spain [22]. Moreover, a previous study [23]
revealed that euthyroid subjects with a TSH level in the
high-normal range (2.5-4.5 mIU/L) had higher TG levels
than those with TSH levels in the low-normal range (0.3-
2.5 mIU/L) (1.583 ± 0.082 vs. 1.422 ± 0.024 mmol/L, P =
0.023). We speculated that this association could not be
explained by the levels of FBG alone, because the FBG in
those with high normal TSH were significantly lower
than that in those with TSH in the lower limits of the
normal range. The positive association between FT3 and
log-transformed values of HDL-C in our study was in
accordance with the observations of Ness et al. [24], who
found that triiodothyronine could raise HDL-C in rat.
Furthermore, we found that the TSH level was signifi-
cantly higher in the hypercholesterolemic and hypertri-
glyceridemic subjects than in patients with normal levels
of TC and TG. Similar results have been obtained by
Lai et al. [25], who demonstrated that the TSH level in
the hypertriglyceridemia group was much higher than in
the normal control group. In case of lipid profiles, the
concentrations of TC, TG and non-HDL-C were signifi-
cantly higher in patients whose TSH level were in the
upper limits than those whose TSH levels were in the
lower limits of the normal range. This phenomenon was
supported by the HUNT study [7], which suggested that
within the clinically normal TSH range, the increasing
level of TSH was associated with less favorable lipid
concentrations.
Concerning the risk of dyslipidemia, our data showed
that the subjects with relatively high TSH levels within
the reference range were more likely to have hypercho-
lesterolemia and hypertriglyceridemia, with the ORs of
approximately 1.640 and 1.349. Therefore, according to
these results, even within the normal range, subjects
with relatively high TSH levels might be prone to dysli-
pidemia. More attention should be paid to lipid profiles
of those patients who had relatively higher serum TSH
levels, even within the normal range.
The detailed mechanisms responsible for the effects of
TSH on the lipid profile remained unclear. Traditionally,
the main function of TSH is to stimulate the synthesis
and release of thyroid hormones in the thyroid gland via
the specific cell membrane receptor-TSHR. It is now
recognized that TSHR is expressed widely in a variety of
Figure 2 Association between serum TSH levels and lipid
profiles in euthyroid non-smokers with newly diagnosed
asymptomatic CHD. (a) Prevalence of abnormal lipid profiles by
categories of different TSH levels within the normal range. *P < 0.05
vs. G1; **P < 0.01 vs. G1 (b) Comparison of serum TSH levels
between normal and abnormal groups according to lipid profiles.
*P < 0.05 vs. normal group and **P < 0.01 vs. normal group.
Table 5 Logistic regression of serum TSH level and risk of
dyslipidemia in 406 euthyroid non-smokers with newly
diagnosed asymptomatic CHD
B SE OR (95%CI of OR) P
hypercholesterolemia 0.494 0.160 1.640(1.199-2.243) 0.002
hypertriglyceridemia 0.299 0.126 1.349(1.054-1.726) 0.017
Low HDL-C 0.121 0.201 1.129(0.671-1.675) 0.547
High LDL-C 0.132 0.257 1.141(0.689-1.890) 0.609
Data are coefficient (B), corresponding standard error (SE), odds ratio (OR) and
95% confidence interval (CI).
Adjusted for sex, age, drinking history, history of diabetes, history of
hypertension, fasting blood glucose and uric acids.
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
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and adipose tissue [26], and act as a physiological regu-
lator in the growth and development of adipocytes [27].
More importantly, emerging evidence suggests that TSH
not only acts on the thyroid gland, but also targets on
several other organs and tissues. The mechanisms for
the regulation of cholesterol homeostasis include effects
on biosynthesis, uptake, and metabolism; and the liver is
vital for both endogenous cholesterol synthesis and
elimination [28]. Previously, our laboratory [29] demon-
strated that TSHR is functionally present in both human
and rat hepatocytes. A late study [13] revealed that TSH
promoted the expression of HMGCR, the rate-limiting
enzyme in cholesterol synthesis in liver cells. Based on
these findings, we assumed that TSH, even within the
normal range, might act through TSHR expressed on
hepatocytes to up-regulate the expression of HMGCR
resulting in increased TC levels in CHD patients. More-
over, we also speculated that there might be other
mechanisms involved in the regulation of lipid profiles
by TSH.
To date, the pathophysiological role of TSH per se on
the cardiovascular system remains unclear. The adminis-
tration of recombinant human TSH has been reported to
be associated with the acute impairment of endothelial
function in patients without evidence of functional thyr-
oid tissue [30]. Considering the elevated levels of TC, TG
a n dn o n - H D L - Ca n dt h ei n c r e a s e dp r e v a l e n c eo f
hypercholesterolemia among patients whose TSH levels
were in the upper limits, we hypothesized that high-nor-
mal TSH might have harmful effects on cardiovascular
health. Meanwhile, we should also note that all current
associations between TSH and lipid profiles have been
weak to modest, and thus the detailed mechanism and
clinical implications about the effects of TSH on the lipid
profile and CHD remains to be elucidated.
The main limitation of this study is its small size.
Furthermore, the thyroid status was classified in all
patients based on one blood test. Thus, some individuals
with transient TSH elevations might have been misclas-
sified. Further studies should involve repeated TSH test-
ing. In addition, with a retrospective study that did not
include follow-up, we were unable to determine whether
differences in TSH represent an actual risk factor for
CHD. In the statistical analysis, the relatively simple
multivariate regression models we used explained only a
limited amount of variations in the serum lipid profiles.
In the future, large-scale studies with longer follow-up
peroids will be needed to estimate the real impact of
this association and its clinical significance.
In summary, we found that the TSH level was posi-
tively and linearly correlated with the TC, non-HDL-C
and TG levels, and the prevalence of hypercholesterole-
mia and hypertriglyceridemia in non-smokers in a
Chinese population with newly diagnosed asymptomatic
CHD. Our study indicated that even within the normal
range, TSH in the upper limits might exert adverse
effects on the lipid profile and thus might represent a
risk factor for hypercholesterolemia and hypertriglyceri-
demia in these patients. In the treatment of CHD and
dyslipidemia, thyroid function (especially the serum
TSH level) should be monitored and maintained in the
relatively low-normal range. Further large prospective
studies are needed to clarify the above relationship and
to confirm its clinical implications.
Methods
Study design and sampling
We conducted a retrospective study with subjects from
the health centre of Qianfoshan Hospital or Shandong
Provincial Hospital (Shandong, China) between January
2004 and September 2010. The study was carried out in
compliance with the Declaration of Helsinki.
A total of 921 subjects with newly diagnosed asympto-
matic CHD, 45-88 years were involved. The exclusion
criteria include: (1) patients without information on vital
status or with missing data on serum TSH or thyroxine
levels(n = 66); (2) patients taking medications that
might affect FT4 or TSH levels or lipid profiles (such as
thyroid hormones, anti-thyroid drugs, iodine, amiodar-
one, estrogens, androgens, steroid hormones, statins,
and fibrates)(n = 68); (3) patients who had neurologic
diseases, hepatic disorders, renal disorders, or euthyroid
sick syndrome which is characterized by abnormal low
serum FT3 but normal FT4 and TSH (n = 98); (4) smo-
kers, including both present and past tobacco users (n =
168). Among the remaining 521 non-smokers with
newly diagnosed asymptomatic CHD, 406 euthyroid
subjects (187 males, 219 females) were recruited as the
study subjects.
Data collection
Data were obtained from medical records. All the
patients were stable at the moment of blood samples
collection, as none of them were receiving heparin,
diuretics or suffering from acute illness, which might
influence the accuracy of thyroid hormone assay. The
levels of FT3, FT4, TSH, anti-thyroglobulin antibody
(anti-TG) and anti-thyroid peroxidase antibody (anti-
TPO) were measured by using an electrochemilumines-
cence immunoassay (Elecsys 2010, Roche, Basel, Swit-
zerland) with intra- and inter-assay coefficients of
variation of less than 5%. The laboratory reference
ranges for TSH, FT4, and FT3 were 0.27-4.2 mIU/L, 12-
22 pmol/L, and 3.1-6.8 pmol/L, respectively. The lipid
profile, fasting blood glucose (FBG) and uric acid (UA)
level were measured using an automatic biochemistry
analyser (OLYMPUS AU5400, Olympus, Japan) and
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Page 6 of 8commercial kits. All patients were asked to rest at least
30 minutes and then in a sitting position, the blood
pressure of their right arm was measured twice with a
desk-model sphygmomanometer. There was a 3-minutes
interval between the two measurements for each partici-
pant, and the mean value of the two measurements was
used as systolic bold pressure (SBP) and diastolic blood
pressure (DBP). The rest and exercise stress ECG were
assessed by two trained cardiologists who were unaware
of the clinical presentation of the patients.
Diagnostic criteria
(1) Thyroid status was diagnosed according to data pre-
viously published in Chinese [31]: Euthyroidism is
defined as TSH within 0.3-4.8 mIU/L and FT4 and FT3
within the above laboratory reference ranges. (2) Asymp-
tomatic CHD patients were diagnosed according to the
Monica criteria [32]: two or more ECG showing specific
changes without suggestive symptoms, and confirmed by
the presence of at least one lesion with ≥50% luminal ste-
nosis by coronary angiography. Abnormal ECG findings
include the ST segment abnormalities, T wave abnormal-
ities, and other abnormalities indicate myocardium ische-
mia. (3) Dyslipidemia: Fasting TC > 5.18 mmol/L (200
mg/dl, hypercholesterolemia), fasting TG > 2.27 mmol/L
(200 mg/dl, hypertriglyceridemia), fasting HDL-C < 1.04
mmo/L (40 mg/dl, low-HDL-C) in male or < 1.29 mmol/
L (50 mg/dl, low-HDL-C) in female, fasting LDL-C >
2.59 mmol/L(100 mg/dl, high LDL-C) [33]. (4) Non-smo-
kers were defined as never daily use of tobacco.
Grouping of the subjects
Because Teng et al. [31] indicated that a baseline TSH
level of 1.0-1.9 mIU/L is an optimal interval to ensure a
low incidence of clinical thyroid diseases within five
years, and lower limits for normal TSH at 2.5 mIU/L
have been suggested based on epidemiological studies
[34], we divided those euthyroid patients into four cate-
gories: G1(lower limits of TSH, 0.3-0.99 mIU/L), G2
(TSH 1.0-1.89 mIU/L), G3(TSH 1.9-2.49 mIU/L) and
G4 (upper limits of TSH 2.5-4.8 mIU/L). Furthermore,
to compare TSH levels among euthyroid subjects with
varying lipid profiles, all subjects were classified as
abnormal or normal according to the lipid levels.
Statistical analysis
Before statistical analysis, the normality of the distribu-
tion and the homogeneity of the variances were evalu-
ated using Kolmogorov-Smirnov test and Levene’st e s t ,
respectively. Data are presented as means ± standard
deviations (SD) or medians with interquartile ranges in
the case of a skewed distribution. Statistical analysis
were performed with ANOVA followed by a multiple-
comparison test for subgroups by LSD. The difference
of TSH within normal range between normal and
abnormal lipid groups was tested by Mann-Whitney
test. The log transformation of lipid parameters was per-
formed to correct the skewed distribution [35]. The
relationships between sex, age, history of DM, history of
hypertension, drinking, TSH, FT3, FT4, FBG, UA and
the log-transformed lipid profile were assessed by simple
correlation analysis. Stepwise multiple linear regression
analysis was performed to estimate the influence of the
above parameters on the lipid profile. Because FT4
(FT3) and TSH are closely correlated, we did not use
FT4 and FT3 in the same model with TSH. Model 1
includes TSH and other parameters except FT3 and
FT4, while model 2 includes FT3, FT4 and other para-
meters except TSH. The results are expressed as beta
(b)- coefficients with 95% confidence intervals (CI)
denoting the SD change in terms of lipid profile markers
per unit increase in the TSH level. Backward stepwise
logistic regression was used to evaluate the odds ratio
(OR) of dyslipidemia in relation to serum TSH. The
level of statistical significance was set at P < 0.05, except
for the regression analysis, in which P <0 . 1 0w a ss e ta s
the cut-off point. All the above analyses were conducted
with the use of SPSS software (SPSS Inc., Chicago, IL,
USA), in version 17.0.
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